Promising Response Rates Build Excitement for CAR T-Cell Therapy in Myeloma

  Oct 31 2020 Tagged Nurses, CAR-T, MM

Adults 4

CAR T-cell therapy is poised to transform the treatment paradigm of relapsed/refractory multiple myeloma now that multiple products are exhibiting high and complete response (CR) rates, said Faiz Anwer, MD, who added that further research may improve safety, prolong responses, and provide insight into resistance mechanisms. 

“Due to the combination of specificity and cytotoxicity, we are seeing very high overall response rates [with CAR T-cell therapy],” said Anwer. “These response rates are variable, but in the range of 80% to 100%. The majority of these responses are very deep, [with most] patients achieving minimal residual disease [MRD] negativity. Achieving MRD negativity is the best outcome that we can expect from any therapy.”

In an interview with Oncology Nursing News' sister publication, OncLive, during the 2020 Institutional Perspectives in Cancer webinar on hematologic malignancies, Anwer, an oncologist, physician-scientist, and stem cell transplant staff physician at the Taussig Cancer Center of Cleveland Clinic, a member of the Hematopoietic and Immune Cancer Biology Program at Case Comprehensive Cancer Center, and an associate professor in the Department of Medicine at the School of Medicine at Case Western Reserve University, discussed the growing role of CAR T-cell therapy in multiple myeloma and areas of unmet need. 

Read the full article featured in OncLive here 

Last Updated on Thursday 26 November 2020.